| Literature DB >> 28701159 |
Vu Quoc Dat1,2,3, Hieu Ngoc Vu4, Hung Nguyen The4, Hoa Thi Nguyen4, Long Bao Hoang5, Dung Vu Tien Viet5, Chi Linh Bui4, Kinh Van Nguyen6, Trung Vu Nguyen4,6, Dao Tuyet Trinh6, Alessandro Torre5, H Rogier van Doorn5,7, Behzad Nadjm5,7, Heiman F L Wertheim5,7,8.
Abstract
BACKGROUND: Bloodstream infections (BSIs) are associated with high morbidity and mortality worldwide. However their aetiology, antimicrobial susceptibilities and associated outcomes differ between developed and developing countries. Systematic data from Vietnam are scarce. Here we present aetiologic data on BSI in adults admitted to a large tertiary referral hospital for infectious diseases in Hanoi, Vietnam.Entities:
Keywords: Burkholderia pseudomallei; Gram-negative bacteria; Streptococcus suis; Vietnam; bacteremia; bloodstream infection; drug resistance, bacterial; sepsis
Mesh:
Substances:
Year: 2017 PMID: 28701159 PMCID: PMC5508750 DOI: 10.1186/s12879-017-2582-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flowchart of BSI episodes and classification of BSI by location of acquisition. Classification based on the first isolate during hospitalization. HABSI: Hospital-acquired bloodstream infection; CABSI: Community-acquired bloodstream infection. a Contaminant episodes included 22 episodes of B. cepacia, 25 episodes of Alcaligenes spp., 7 episodes of viridans group streptococci, 8 episodes of Ralstonia picketii, 6 episodes of Pseudomonas species (P. fluorescens, P. putida and P. stutzeri) 4 episodes of Chryseobacterium spp., 3 episodes of S. maltophilia, 3 episodes of Serratia marcescens, 3 episodes of Ochrobactrum antrhopi, 2 episodes of Sphingomonas paucimobilis, 1 episode of each E. coli, K. pneumonia, Corynebacterium spp. and Chryseomonas luteola
Characteristics of the clinical study population
| Total | Community acquired BSI | Hospital acquired BSI | |
|---|---|---|---|
|
|
|
| |
|
|
| ||
| Age – median (IQR) | 48 (36–60) | 48 (36–60) | 50 (32–60) |
| Female sex | 132 (27.7%) | 122 (30.6%) | 10 (13%) |
| Any ICU admission during NHTD hospitalisation | 245 (51.4%) | 190 (47.5%) | 55 (71.4%) |
| Any history of medical condition | 142 (29.8%) | 109 (27.3%) | 33 (42.9%) |
| Liver disease | 68 (14.3%) | 54 (13.5%) | 14 (18.2) |
| Diabetes | 34 (7.1%) | 25 (6.3%) | 9 (11.7%) |
| Moderate or severe renal disease | 9 (1.9%) | 6 (1.5%) | 3(3.9%) |
| HIV infection | 30 (6.3%) | 21 (5.3%) | 9 (11.7%) |
| Other morbidity | 10 (2.1%) | 8 (2%) | 2 (2.6%) |
| Long-term corticosteroid use | 8 (1.7%) | 7 (1.8%) | 1 (1.3%) |
| Self-report alcoholism | 67(14%) | 56 (14%) | 11 (14.3%) |
| Intravenous drug use | 23 (4.8%) | 17 (4.3%) | 6 (7.8%) |
aLiver disease was defined in a patient with chronic hepatitis and/or cirrhosis
bModerate or severe renal disease was defined in a patient with baseline creatinine >3 mg% (265 umol/l), dialysis or kidney transplantation
Aetiology of bloodstream infections
| Pathogen | All patients | Sampled clinical cases | |||
|---|---|---|---|---|---|
| Total | CABSI | HABSI | pg | ||
|
|
|
|
| ||
| Enterobacteriaceae | 345 (46.7%) | 245 (51.4%) | 200 (50%) | 45 (58.4%) | 0.213 |
|
| 129 (17.5%) | 110 (23.1%) | 88 (22%) | 22 (28.6%) | 0.237d |
|
| 128 (17.3%) | 73 (15.3%) | 64 (16%) | 9 (11.7%) | 0.391 |
|
| 45 (6.1%) | 30 (6.3%) | 24 (6%) | 6 (7.8%) | 0.606 |
| serovar Typhi | 10 (1.4%) | 4 (0.8%) | 4 (1.00%) | 0 | 1 |
| non-typhi Salmonella | 35 (4.7%) | 26 (5.5%) | 20 (5%) | 6 (7.8%) | 0.407 |
|
| 16 (2.2%) | 12 (2.5%) | 9 (2.3%) | 3 (3.9%) | 0.421 |
|
| 16 (2.2%) | 12 (2.5%) | 8 (2.0%) | 4 (5.2%) | 0.112 |
| Other | 11 (1.5%) | 8 (1.7%) | 7 (1.8%) | 1 (1.3%) | 1 |
| Non-Enterobacteriacae | 156 (21.1%) | 99 (20.8%) | 78 (19.5%) | 21 (27.3%) | 0.127 |
|
| 71 (9.6%) | 47 (9.9%) | 39 (9.8%) | 8 (10.4%) | 0.836 |
|
| 34 (4.6%) | 14 (2.9%) | 12 (3.0%) | 2 (2.6%) | 1 |
|
| 15 (2.0%) | 13 (2.7%) | 13 (3.3%) | 0 | |
|
| 16 (2.2%) | 13 (2.7%) | 9 (2.3%) | 4 (5.2%) | 0.240 |
|
| 16 (2.2%) | 10 (2.1%) | 3 (0.8%) | 7 (9.1%) | <0.001 |
|
| 4 (0.5%) | 2 (0.4%) | 2 (0.5%) | 0 | 1 |
| Gram-positive isolates | 229 (31.0%) | 126 (26.4%) | 115 (28.8%) | 11 (14.3%) | 0.007 |
|
| 110 (14.9%) | 41 (8.6%) | 34 (8.5%) | 7 (9.1%) | 0.826 |
|
| 56 (7.6%) | 43 (9.0%) | 43 (10.8%) | 0 | - |
|
| 37 (4.9%) | 23 (4.8%) | 21 (5.3%) | 2 (2.6%) | 0.559 |
|
| 7 (0.9%) | 5 (1.0%) | 4 (1.0%) | 1 (1.3%) | 0.587 |
|
| 21 (2.8%) | 11 (2.3%)b | 10 (2.5%) | 1 (1.3%) | 1 |
|
| 9 (1.2%) | 7 (1.5%) | 7 (1.8%) | 0 | 0.604 |
|
| 14 (1.9%) | 12 (2.5%) | 10 (2.5%) | 2 (2.6%) | 1 |
|
| 12 (1.6%) | 7 (1.5%) | 7 (1.8%) | 0 | 0.604 |
| Polymicrobialf | 8 (1.1%) | 7 (1.5%) | 7 (1.8%) | 0 | 0.604 |
aIncluding 3 cases with Klebsiella oxytoca, 3 cases with Proteus mirabilis, 2 cases with Escherichia hermannii, 1 case with Citrobacter freundii, 1 case with Morganella morganii and 1 case with Vibrio vulnificus
bIncluding 12 cases with A. baumannii, 3 cases with A. lwoffii and 1 case with A. junii
cIncluding 1 case for Elizabethkingia meningosepticum, Haemophilus influenzae, Pasteurella multocida and Neisseria meningitidis,
dCases with viridans group infection had at least two positive blood culture or single positive blood culture plus vegetation on echocardiography
eIncluding 4 cases with Rhodococcus equi, 3 cases with Listeria monocytogenes, 2 cases with Aerococcus viridians, 2 cases with Listeria spp. and 1 case with Listeria innocua
fIn 8 dual infection cases, 3 HIV infected cases had co-infection with Talaromyces marneffei and S. aureus, Escherichia hermannii or Salmonella group D; 1 case with S. aureus and K. pneumoniae, 1 case with Enterococcus faecalis and viridans streptococci, 1 case with E. coli and K. pneumoniae and 1 case with S. aureus and E. coli co-infection
g p values were calculated using Chi-square test or Fisher’s Exact test as appropriate
Resistance among K. pneumoniae from BSI
| Resistance | All isolates | Sampled clinical cases | |||
|---|---|---|---|---|---|
| Total | CABSI | HABSI |
| ||
| Any extended spectrum cephalosporin | 19/133 (14.3%) | 13/112 (11.6%) | 8/90 (8.9%) | 5/22 (22.7%) | 0.128 |
| ESBL production | 15/122 (12.3%) | 9/101 (8.9%) | 5/82 (6.1%) | 4/19 (21.1%) | 0.062 |
| Others | 4/133 (3.0%) | 4/112 (3.6%) | 3/90 (3.3%) | 1/22 (4.5%) | 1 |
| Any carbapenem | 1/131 (0.8%) | 1/109 (0.9%) | 0/89 (0%) | 1/20 (5%) | 0.183 |
| Any aminoglycoside | 17/131 (13.0%) | 13/109 (11.9%) | 9/89 (10.1%) | 4/20 (20%) | 0.252 |
| Any fluoroquinolone | 11/131 (8.4%) | 8/109 (7.3%) | 4/89 (4.5%) | 4/20 (20%) | 0.036 |
| Co-trimoxazole | 24/124 (19.4%) | 19/102 (18.6%) | 14/84 (16.7%) | 5/18 (27.8%) | 0.318 |
a p values were calculated using Fisher’s Exact Test
Resistance among E. coli from BSI
| Resistance | All isolates | Sampled clinical cases | |||
|---|---|---|---|---|---|
| Total | CABSI | HABSI |
| ||
| Any extended spectrum cephalosporin | 72/131 (55.0%) | 45/74 (60.8%) | 39/65 (60%) | 6/9 (66.7%) | 1 |
| ESBL production | 50/111 (45%) | 33/61 (54.1%) | 28/52 (53.8%) | 5/9 (55.6%) | 1 |
| Others | 22/131 (16.8%) | 12/74 (16.2%) | 11/65 (16.9%) | 1/9 (11.1%) | 1 |
| Any carbapenem | 1/130 (0.8%) | 0/73 (0.0%) | 0/64 (0.0%) | 0/9 (0.0%) | - |
| Any aminoglycoside | 30/129 (23.3%) | 15/73 (20.5%) | 14/64 (21.9%) | 1/9 (11.1%) | 0.675 |
| Any fluoroquinolone | 41/129 (31.8%) | 26/72 (36.1%) | 22/63 (34.9%) | 4/9 (44.4%) | 0.714 |
| Cotrimoxazole | 62/90 (68.9%) | 27/38 (71.1%) | 24/33 (72.7%) | 3/5 (60.0%) | 0.615 |
| Fosfomycin | 1/52 (1.9%) | 1/44 (2.3%) | 1/38 (2.6%) | 0/6 (0%) | - |
a p values were calculated using Fisher’s Exact Test
Resistance among S. aureus from BSI
| Susceptibility | All isolates | Sampled clinical cases | |||
|---|---|---|---|---|---|
| Total | CABSI | HABSI |
| ||
| Methicillin (MRSA) | 40/108 (37%) | 12/38 (31.6%) | 12/31 (38.7%) | 0/7 (0%) | 0.074 |
| Erythromycin | 39/72 (54.2%) | 11/23 (47.8%) | 10/18 (55.6%) | 1/5 (20%) | 0.317 |
| Clindamycin | 56/109 (51.4%) | 21/40 (52.5%) | 18/23 (54.5%) | 3/7 (42.9%) | 0.689 |
| Chloramphenicol | 35/105 (33.3%) | 14/38 (36.8%) | 11/31 (35.5%) | 3/7 (42.9%) | 1 |
| Gentamicin | 18/76 (23.7%) | 9/26 (34.6%) | 7/21 (33.3%) | 2/5 (40%) | 1 |
| Ciprofloxacin | 19/99 (19.2%) | 7/33 (21.2%) | 6/28 (21.4%) | 1/5(20%) | 1 |
| Levofloxacin | 18/103 (17.5%) | 9/40 (22.5%) | 6/13 (18.2%) | 3/7 (42.9%) | 0.316 |
| Co-trimoxazole | 8/62 (12.9%) | 5/28(17.9%) | 4/21 (19%) | 1/7 (14.3%) | 1 |
| Rifampicin | 10/95 (10.5%) | 6/33 (18.2%) | 5/27 (18.5%) | 1/6 (16.7%) | 1 |
| Vancomycinb | 0/63 (0%) | - | - | - | - |
a p values were calculated using Fisher’s Exact Test
bThe vancomycin susceptibility and the MRSA rate were defined by Minimum Inhibitory Concentrations (MICs) using E-test
Fig. 2Case-fatality by etiology of bloodstream infection (BSI). Error bars represent the 95% confidence interval (CI) for case mortality proportions
Cox proportional hazards model of factors associated with all-cause in-hospital case fatality among patients with bloodstream infections due to a single organism in clinical dataset
| Variable | Hazard ratio (95% CI)a |
|
|---|---|---|
| Gender (male/female) | 1.347 (.857–2.115) | 0.196 |
| Age (1-yr. increment) | 1.008 (0.998–1.01) | 0.118 |
| Aetiology of BSI (gram-positive bacterial infection as reference) | ||
|
| 2.485 (1.546–3.994) | <0.001 |
| Non | 1.931 (1.063–3.50) | 0.031 |
| Acquisition of infection (CABSI as reference) | 1.006 (0.633–0.399) | 0.053 |
| Any co-morbidities | 1.467 (1.017–2.114) | 0.040 |
| Referring from another hospital | 2.049 (1.411–2.975) | <0.001 |
aCases with S. maltophilia infection were excluded from analysis
bHazard ratios and P-values were calculated using Cox proportional hazards model